



Evolut Oncology Program Updates

July 27, 2026

Dear Provider,

SilverSummit Healthplan in collaboration with Evolut is implementing updates to how oncology services are reviewed and administered to enhance the member and provider experience. These changes reflect a shared commitment to improving efficiency, reducing administrative burden, and supporting timely, clinically appropriate care decisions.

What's Changing

Denial Determinations for Oncology Services

Effective 12/01/26, Evolut will issue denial determinations for oncology authorization requests that do not meet clinical criteria.

For requests received prior to 12/01/26, Evolut will continue to issue Recommended Adverse Determinations (RADs) when clinical criteria are not met and SilverSummit Healthplan will provide the final determination of the request.

Please continue to submit grievances and appeals directly to SilverSummit Healthplan.

Pharmacy Benefit (Part D) Scope Update

Effective 12/01/26, Evolut's oncology review scope will be limited to medical benefit (Part B) medications only. All pharmacy-dispensed (Part D) drugs must be submitted directly to SilverSummit Healthplan, in accordance with plan guidelines.

Requests received prior to 12/01/26, will be administered by Evolut under the current process.

For questions or additional information, please contact Provider Services at 1.844.366.2880 or reach out to your Provider Engagement Representative.

Sincerely,

SilverSummit Healthplan